Ukraine war: Kyiv claims success as southern fighting intensifies
28-07-2023, 09:38

Font size: [ A+ ] / [ A- ]

Ukraine's military says it has had success on one of the front lines in southeast Ukraine, as Western officials talk of a major thrust taking place.

In a video published by President Zelensky, Ukrainian troops said they had taken the village of Staromaiorske.

Earlier, Ukraine's military said it was "solidifying positions" it had reached in the same area, east of the city of Zaporizhzhia.

Ukraine has not confirmed that it has beefed up its counter-offensive.

But Russian President Vladimir Putin said Ukraine's attacks had "significantly" intensified.

He told reporters in St Petersburg they had had no success: "All counter-offensive attempts were stopped, and the enemy was pushed back with high casualties."

Russian-backed militia leader Aleksandr Khodakovsky contradicted Mr Putin, saying Ukraine had methodically shelled Staromaiorske for several days and made gains, holding on to the outskirts and pushing on.

Russian military blogger WarGonzo said the news was disturbing as Staromaiorske was a key Russian outpost on the front line in the south-eastern region of Zaporizhzhia.

Russia's war bloggers are considered an alternative source of information from the front line in the absence of official accounts.

Ukraine's counter-offensive began on a number of fronts last month but has seen very few clear gains so far. Kyiv's generals have warned that fast results are almost impossible because of Russia's fortified defensive lines and rows of minefields.

The man in charge of operations in the south, Gen Oleksandr Tarnavskyi, has told the BBC that "any defence can be broken but you need patience, time and skilful action".

Although there has so far been no word from Kyiv, unnamed US defence officials have told American outlets that a new push has begun in the Ukrainian counter-offensive.

The US-based Institute for the Study of War said an "intense frontal assault" had been launched towards Robotyne, to the south-east of Zaporzhhia city and some 10km (6 miles) south of the town of Orikhiv.

WarGonzo said Ukrainian forces were bombarding Russian forces on the northern and eastern outskirts of Robotyne, although that was not confirmed by Kyiv. The Russian defence ministry said Ukrainian attacks there had been repelled.

Ukraine's Defence Minister Hanna Maliar has spoken of a "gradual advance" in Ukraine's push towards the two cities of Melitopol and Berdyansk. Any advance towards either city would mark a decisive step in the military campaign.

If Ukraine's forces are able to make further progress in Robotyne, the next settlement to the south is Tokmak, on the road to Melitopol.

One area where Ukraine has said it is advancing is south of Bakhmut, the eastern city captured by Russian forces after a long and ferocious battle that reduced it to ruins.

Ms Maliar said Ukrainian forces were gradually moving forward and fighting was taking place in three villages on the front line directly south of the city. "The fighting is pretty harsh. Enemy fire is intense," she said.

In a separate development, Ukraine's parliament has voted to extend martial law for another 90 days, barring men of fighting age from leaving the country.

Martial law was imposed when Russia launched its full-scale invasion of Ukraine in February 2022. The vote also means parliamentary elections due in October will be delayed.

 

Comments: 3055
#1635   Kira
      
steroid anavar

References:


templeton-high.mdwrite.net
7 October 2025 10:09
#1634   Annie
      
Also visit my web page - All Thunderkick
Games In One Place
7 October 2025 06:24
#1633   Wendell
      
anabolic steroids short term effects

References:


md.swk-web.com
7 October 2025 06:20
#1632   Esperanza
      
7 October 2025 04:48
#1631   Osvaldo
      
7 October 2025 02:57
#1630   Clinton
      
BPC‑157 is a synthetic peptide that mimics a naturally occurring body protein fragment.
It has been studied for its potential to accelerate healing
in tissues such as muscle, tendon, ligament, and
nerve, as well as its anti-inflammatory properties.
Researchers have found that it can promote angiogenesis, reduce oxidative stress,
and modulate growth factors involved in tissue repair.
Although most of the data come from animal models, some anecdotal reports suggest benefits for athletes, people with chronic injuries, or those recovering from surgery.




Best Form of BPC‑157 Revealed: Injectable, Capsule, or Oral?




Injectable
The injectable form is generally considered the gold standard because it delivers
the peptide directly into the bloodstream or the site of injury.

This method bypasses the digestive tract and ensures that a higher
concentration reaches target tissues. Many users report faster results with
injections, especially for acute injuries such as tendon tears or joint pain. The most common dosage protocol involves 200 to
400 micrograms per day, divided into two or three injections.





Capsule
Capsules are convenient for those who prefer not to handle needles.
However, the oral route subjects BPC‑157 to enzymatic degradation in the stomach and liver, which
can drastically reduce bioavailability. Some manufacturers claim that their capsules use a protective coating or a carrier molecule to improve absorption, but independent verification is limited.
The typical dosage for capsules ranges from 500 to 1,000 micrograms per day.




Oral
Pure oral tablets are the least effective form because the peptide is highly susceptible to proteases in the gut.
Even if you take large doses (up to 2 milligrams), only a
tiny fraction may reach systemic circulation. Oral preparations might still provide
some benefit for mild, chronic conditions, but they generally require much higher amounts and longer treatment periods.




What to Consider When Choosing a BPC‑157 Form



Target Condition
If you’re dealing with an acute injury or need rapid tissue repair,
injectable is usually the best choice. For long‑term maintenance or mild inflammation,
capsules may suffice.



Convenience vs. Effectiveness
Needle phobia or discomfort can steer users toward capsules or oral forms.
Weigh how much effort you’re willing to invest against the expected benefit.
Injections require a sterile environment and proper technique; capsule usage
is simpler but potentially less potent.



Cost
Injectable solutions tend to be more expensive
per milligram because they contain stabilizing agents and are sold in pre‑filled syringes.
Capsules may appear cheaper, yet you might need larger quantities to achieve the same effect, which can offset savings.




Safety Profile
All forms of BPC‑157 are generally well tolerated with few reported side effects.
However, injectable use carries a risk of local irritation or
infection if not administered properly. Capsule
and oral routes eliminate these risks but may introduce gastrointestinal discomfort for some users.




Regulatory Status
BPC‑157 is not approved by major regulatory agencies such as the FDA for medical
use. Its sale as
a research chemical means that quality can vary widely between manufacturers.
Prioritize reputable suppliers with third‑party testing, especially when purchasing injectable formulations.




Dosage and Duration
Injectable protocols often recommend 200 to 400 micrograms daily over 2 to 4 weeks, depending on injury severity.

Capsule regimens usually prescribe higher daily amounts (500–1,000 micrograms) for a longer period (4 to 6 weeks).
Oral dosing is even less predictable; some users take up to
2 milligrams per day with uncertain outcomes.



Quick Takeaways



BPC‑157 shows promise in accelerating tissue repair and reducing inflammation,
but evidence remains largely preclinical.

Injectable forms deliver the peptide most efficiently and are preferred
for acute injuries.

Capsules offer convenience at the cost of reduced bioavailability; they may work
for chronic or mild conditions.

Pure oral tablets are least effective due to digestive degradation, yet they remain an option for those who cannot use
injections.

When choosing a form, consider your injury
type, tolerance for needles, budget, safety, and regulatory concerns.






Ultimately, the best choice depends on individual needs
and circumstances; consulting with a healthcare professional familiar with
peptide therapies can help tailor the most appropriate approach.
7 October 2025 01:16
#1629   Cherie
      
BPC‑157 is a synthetic peptide that has gained attention for its potential healing properties in various tissues such as muscle, tendon, nerve and
ligament. Because it is not yet approved by regulatory authorities for human use, the
information available about its safety profile comes largely
from animal studies, anecdotal reports, and a small number
of early-phase clinical investigations. Users
who are considering BPC‑157 should be aware that while many describe remarkable benefits, there is also a range of possible
side effects that can occur.



BPC 157
Side Effects
: What to Watch For





Mild local reactions at the injection site such as redness, swelling or discomfort.

In some cases the area may feel warm or tender for a few hours after administration.


Temporary changes in appetite or digestive function. A small number of users have reported mild nausea, stomach upset,
or an altered sense of taste shortly after taking BPC‑157.



Hormonal shifts are possible because peptides can influence
growth factor pathways. Reports include transient fluctuations in testosterone
levels and changes in menstrual cycle patterns for women.


Rarely, people experience headaches or dizziness, which may
be related to systemic absorption or the stress response triggered by peptide therapy.



In animal models, high doses of BPC‑157 have been linked with
altered liver enzyme activity, suggesting a potential impact on hepatic function. While this has not yet been confirmed
in humans, monitoring liver markers could be prudent for long-term
users.


Some anecdotal evidence indicates that BPC‑157 may increase the risk
of bruising or bleeding at injury sites because it promotes rapid tissue
repair and angiogenesis. Individuals with clotting disorders should exercise caution.


Immune responses can arise when peptides are introduced into the body.
Though rare, allergic reactions such as rash, itching
or swelling have been reported by a few users.


Psychological effects, including mild mood changes, have occasionally been mentioned in forums
discussing peptide use, but no systematic studies have confirmed this association.



Benefits of BPC‑157

The primary appeal of BPC‑157 lies in its purported regenerative capabilities.
In preclinical models it has shown:





Accelerated healing of muscle tears and tendon ruptures with improved collagen alignment.



Reduced inflammation in joint tissues and cartilage, potentially alleviating arthritis
symptoms.


Protection of the gastric lining, which can be useful for individuals prone to ulcers or
gastritis.


Promotion of nerve regeneration after peripheral nerve injury, often resulting in faster functional recovery.




Cardioprotective effects, including reduced damage after ischemic events and
improved cardiac muscle repair.


Enhancement of vascular integrity and blood flow to damaged tissues through stimulation of angiogenic factors.




What is BPC‑157?

BPC‑157 (Body Protective Compound 157) is a pentadecapeptide derived from a protein found in human gastric juice.
Its amino acid sequence mimics part of the naturally occurring body
protective compound, which is believed to play a role in wound healing and tissue repair.

Because it is a relatively small peptide, BPC‑157 can be administered subcutaneously or intramuscularly and has
a short half-life that allows for rapid distribution to target tissues.




Researchers are investigating its mechanisms of action, including modulation of the vascular endothelial
growth factor (VEGF) pathway, stabilization of platelet-derived
growth factor (PDGF), and interaction with the nitric oxide
system. These pathways collectively contribute to the peptide’s
ability to stimulate cellular proliferation, migration, and
extracellular matrix remodeling.



While BPC‑157 shows promise in a range of therapeutic contexts—from sports injuries
to gastrointestinal disorders—the lack of large-scale human trials means that
safety data remain incomplete. Anyone considering this therapy
should consult with a qualified healthcare professional, discuss potential risks and benefits, and ensure that the product is sourced from reputable suppliers who adhere to good manufacturing practices.
7 October 2025 00:55
#1628   Mickie
      
7 October 2025 00:15
#1627   Garnet
      
Also visit my web page: free poker
7 October 2025 00:02
#1626   Darell
      
legal steroids 2016

References:


md.entropia.de
6 October 2025 23:45
#1625   Caroline
      
6 October 2025 23:41
#1624   Angelo
      
my webpage free poker
6 October 2025 21:18
#1623   Willie
      
Here is my web blog - pokertube
6 October 2025 19:52
#1622   Lilly
      
Also visit my web page ... highstakes 777
6 October 2025 18:31
#1621   Leon
      
Here is my blog online poker canada
6 October 2025 16:17
#1620   Kimberly
      
My web page :: poker Online
6 October 2025 15:32
#1619   Marlon
      
I'm really enjoying the design and layout
of your website. It's a very easy on the eyes which makes it much more pleasant for me to come here and visit more often. Did you hire out a designer to create your theme?

Great work!

My blog ... Online Poker
6 October 2025 15:18
#1618   Chas
      
Feel free to surf to my web site :: poker high stakes
6 October 2025 15:12
#1616   Stefanie
      
My webpage :: High Stake Poker
6 October 2025 11:26
Add Comments

Name:*
E-Mail:
  Geo Keyboard  
 

Dear reader, guardian.ge welcomes your comments. Please express your views on topic and be respectful of others.

bold italic underline strike | align left centered align right | Ensert smilies insert linkInsert protected URL Choice the color | hidden text insert quote Convert selected text from transliteration to Cyrillic alphabet Insert spoiler

Code: *


Back1 ... 68 69 70 71 72 73 74 75 76 ... 153Next